11 – 20 of 26
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
- Contribution to journal › Article
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
- Contribution to journal › Article
- 2019
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
- Contribution to journal › Article
-
Mark
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
(2019) In British Journal of Haematology
- Contribution to journal › Article
- 2018
-
Mark
Mantle cell lymphoma strategies in primary treatment
- Thesis › Doctoral thesis (compilation)
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
- Contribution to journal › Article
- 2017
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
- Contribution to journal › Article
- 2016
-
Mark
A Molecular Dissection of Mantle Cell Lymphoma - From gene expression analysis to functional evaluation of selected targets
(2016)
- Thesis › Doctoral thesis (compilation)
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
- Contribution to journal › Article
